Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.

Annual review of medicine - 14 Jan 2017

Naggie Susanna, Muir Andrew J

Abstract excerpt

The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of medicine's greatest advancements. Viral eradication rates are pushing 100% for many HCV-infected populations, including patients with HIV/HCV coinfection,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Coinfection
Share to Kidney Failure, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Cirrhosis

Share to Liver Transplantation

Share to Recurrence

Share to Secondary Prevention

Share to Treatment Failure

Source

Identifiers

PMID: 27686017
DOI: 10.1146/annurev-med-052915-015720

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.PMID 27686017Read ↗

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Novel therapies for hepatitis C - one pill fits all?Semantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

What does the pharmacological future of treating chronic hepatitis C look like?Semantic proximity Read ↗

New hepatitis C therapies: the toolbox, strategies, and challenges.Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.Semantic proximity Read ↗

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity Read ↗

Update on hepatitis C treatment: systematic review of clinical trials.Semantic proximity Read ↗

Advances in hepatitis C therapies.Semantic proximity Read ↗

Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.Semantic proximity Read ↗

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.